TROJAN LAW OFFICES OBTAINS PATENT APPROVAL FOR FETUIN DERIVED POLYPEPTIDE TO TREAT CANCER
Posted in / Firm Announcement / - on November 4, 2008
LOS ANGELES – Trojan Law Offices, an intellectual property law firm with expertise in biomedical sciences announces the issuance of United States Patent No. 7,445,784 for “Polypeptide For The Treatment of Cancer And a Method For Preparation Thereof” on behalf of its client, Ambryx Biotechnology, Inc.
“It’s rewarding to see Ambryx obtain yet another patent for its significant discoveries in the treatment of cancer,” commented lead patent counsel, R. Joseph Trojan. “The apoptotic activity of this fetuin derived polypeptide is significant because of its targeted effect on cancer cells, which basically means that it re-programs cancer cells so that they die without harming surrounding cells.”
Ambryx Biotechnology Inc. is a privately-held biomedical company that discovers naturally occurring bioactive peptides which can be used to develop safe and effective therapeutic drug treatment products to be used in cancer and obesity treatment programs.
